Alivio Therapeutics Inc, based in Boston, MA, is a biotechnology company that focuses on developing innovative therapeutic solutions for conditions involving inflammation and fibrosis, such as idiopathic pulmonary fibrosis. With a strong emphasis on research and development, Alivio has generated a portfolio of 28 therapeutic and therapeutic candidates, including two that have received regulatory clearances and a third that is awaiting FDA approval. The company's mission is to advance transformative medicines that improve the lives of individuals living with various medical conditions.
Through its wholly owned programs and collaborations with other entities, Alivio Therapeutics is actively working on addressing central nervous system-related conditions, psychiatric and neurological conditions, solid tumors, blood cancers, and more. The company's innovative approaches include engineering stem cells, developing oral administration methods for peptide therapeutics, and utilizing artificial intelligence technologies. With a commitment to scientific excellence and a focus on patient well-being, Alivio Therapeutics is at the forefront of pioneering new treatments and therapies in the biotechnology industry.
Generated from the website